Improved Quality of Life in Children With Intestinal Failure
Primary Purpose
Intestinal Pseudo-Obstruction, Short Bowel Syndrome, Malabsorption Syndrome Autoimmune Enteropathy
Status
Recruiting
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Stimulance
Sponsored by
About this trial
This is an interventional treatment trial for Intestinal Pseudo-Obstruction
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with congenital malformations or diseases requiring intestinal surgery leading to short bowel syndrome. or
- Diagnosed with conditions and diseases leading to intestinal failure e.g pseudo obstruction.
and
- Treated with parenteral nutrition for >3 months
Exclusion Criteria:
- Patients in need of temporary parenteral nutrition intervention due to illness, e.g. infections.
- Patients with temporary malfunctioning gut due to advanced medical treatment, for example cancer treatment or transplantation
Sites / Locations
- Oslo University HopspitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
No Intervention
Arm Label
Stimulance
Stimulance 6 months
No intervention
Arm Description
4 weeks intervention with Stimulance for all participants
6 months intervention
6 months control group
Outcomes
Primary Outcome Measures
Changes in Quality of life scores before and after treatment with prebiotics
Changes in Pediatric quality of life inventory scores on an analog scale from 0-100 where higher scores means better outcome
Changes in gastro intestinal symptoms scores before and after treatment with prebiotics
Pediatric quality of life inventory Gastro intestinal symptom scale scores on an analog scale from 0-100 where higher scores means better outcome
Changes in familt impact scores before and after treatment with prebiotics
Pediatric quality of life inventory Family Impact Module scores on an analog scale from 0-100 where higher scores means better outcome
Secondary Outcome Measures
Changes in Microbiota
Measured by Short Chain Fatty Acids and microbiota composition
Full Information
NCT ID
NCT04981262
First Posted
June 22, 2021
Last Updated
June 21, 2023
Sponsor
Oslo University Hospital
Collaborators
University of Oslo
1. Study Identification
Unique Protocol Identification Number
NCT04981262
Brief Title
Improved Quality of Life in Children With Intestinal Failure
Official Title
Improved Quality of Life in Children With Intestinal Failure - a Randomised Intervention Trial
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 2, 2021 (Actual)
Primary Completion Date
December 2, 2023 (Anticipated)
Study Completion Date
December 2, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital
Collaborators
University of Oslo
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Children with intestinal failure have a lack of tolerance for food in the intestine. The children are dependent on intravenous nutrition over a long period of time period to ensure growth and development. The condition is characterized by bacterial overgrowth in the intestine, with nausea, vomiting, diarrhea and flatulence as physical symptoms. Mental health is affected in the form of lower quality of life, lack of school participation and less social contact with peers. The investigators own (unpublished) data show that children with intestinal failure have a lower quality of life than healthy people. Standard treatment is antibiotics, but the effect of these is short-lived, and many must have repeated courses. Prebiotics are indigestible carbohydrates (fiber) in foods that positively affect the bacterial flora and promote intestinal health. In this project the investigators want to see if supply of prebiotics can change the bacterial balance, reduce symptoms of bacterial overgrowth and increase quality of life. The study is unique, as Prebiotics have not previously been used in the treatment of intestinal failure. If successful, it can pave the way for a new and better treatment method that can potentially be transferred to other conditions with imbalance in the intestinal flora. The study is a randomized intervention study and is consist of two phases. In phase 1, the effect of 4 weeks of open intervention with prebiotics is studied to establish so-called "proof of concept". Data from phase 1 are used to look at connections between the composition of intestinal flora, nutritional status and bowel function. The intervention involves the use of a prebiotic product (Stimulance, Nutricia), which is added to childs regular food. In phase 2, patients are randomized into two groups. One group will continue with the product for 6 months, while the other group does not receive prebiotics.
Detailed Description
Quality of life, gastrointestinal symptoms and family impact are measured using validated forms for four weeks before intervention phase 1, at start-up and after phase 1, as well as after phase 2. Stool samples are collected at the same time points. Weight, height is measured and blood tests are collected at the start and end of phases 1 and 2. Data on diet and nutritional treatment are collected at the start and end of the two phases. The stool samples are analyzed for short fatty acids (marker for good intestinal health), the composition of the intestinal flora and inflammation markers. Blood samples are analyzed for infection markers, intestinal health markers and nutritional markers. Nutritional data are analyzed for nutrient content and the dependence on nutritional support is calculated.
The investigators expect that the study will lead to an improved quality of life for the patient group through increased tolerance to food in the intestine, reduced antibiotic use and reduction of gastrointestinal symptoms. The project is patient-oriented.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intestinal Pseudo-Obstruction, Short Bowel Syndrome, Malabsorption Syndrome Autoimmune Enteropathy, Bacterial Overgrowth
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Intervention with prebiotics to all participants for 4 weeks. Then randomisation to continue with prebiotics for 6 months or no intervention.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Stimulance
Arm Type
Experimental
Arm Description
4 weeks intervention with Stimulance for all participants
Arm Title
Stimulance 6 months
Arm Type
Experimental
Arm Description
6 months intervention
Arm Title
No intervention
Arm Type
No Intervention
Arm Description
6 months control group
Intervention Type
Dietary Supplement
Intervention Name(s)
Stimulance
Intervention Description
Intervention with Prebiotic supplement
Primary Outcome Measure Information:
Title
Changes in Quality of life scores before and after treatment with prebiotics
Description
Changes in Pediatric quality of life inventory scores on an analog scale from 0-100 where higher scores means better outcome
Time Frame
6 months
Title
Changes in gastro intestinal symptoms scores before and after treatment with prebiotics
Description
Pediatric quality of life inventory Gastro intestinal symptom scale scores on an analog scale from 0-100 where higher scores means better outcome
Time Frame
6 months
Title
Changes in familt impact scores before and after treatment with prebiotics
Description
Pediatric quality of life inventory Family Impact Module scores on an analog scale from 0-100 where higher scores means better outcome
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Changes in Microbiota
Description
Measured by Short Chain Fatty Acids and microbiota composition
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria are:
Diagnosed with congenital malformations or diseases requiring intestinal surgery leading to short bowel syndrome or
Diagnosed with conditions and diseases leading to intestinal failure e.g pseudo obstruction.
And Treated with parenteral nutrition for minimum 60 days within a 74 day period.
Exclusion criteria:
Children in need of temporary advanced nutrition intervention due to illness, e.g. infections.
Children with temporary malfunctioning gut due to advanced medical treatment, for example cancer treatment or transplantation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rut Anne Thomassen
Phone
+ 4722118765
Email
uxruom@ous-hf.no
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Charlotte Brun, MD PhD
Phone
+4722118765
Email
bruan@ous-hf.no
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rut Anne Thomassen
Organizational Affiliation
Oslo University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anne Charlotte Brun, MD PhD
Organizational Affiliation
Oslo University Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Christine Henriksen, PhD
Organizational Affiliation
University of Oslo
Official's Role
Study Chair
Facility Information:
Facility Name
Oslo University Hopspital
City
Oslo
ZIP/Postal Code
0424
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rut Anne Thomassen, MSc
Phone
+4791636452
Email
r.a.thomassen@medisin.uio.no
First Name & Middle Initial & Last Name & Degree
Anne Charlotte Brun, PhD Med
Phone
+4795747071
Email
BRUAN@ous-hf.no
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Improved Quality of Life in Children With Intestinal Failure
We'll reach out to this number within 24 hrs